Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Adolfsson

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Age and Ageing|July 1, 1996
Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based studyA R Helgason, J Adolfsson, P Dickman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
Incidence and survival of rare urogenital cancers in EuropeO Visser, J Adolfsson, S Rossi, et al.
Urology|May 1, 1999
Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mLM Törnblom, U Norming, J Adolfsson, et al.
European Urology|September 23, 1998
Sexual dysfunction associated with the management of prostate cancerJ M Fitzpatrick, R S Kirby, R J Krane, et al.
BJU International|February 27, 2004
Monitoring the ERSPC trialH J De Koning, T Hakulinen, S M Moss, et al.
British Journal of Cancer|September 23, 1998
The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancerO T Jansson, E Morcos, L Brundin, et al.
British Journal of Cancer|June 1, 2001
p53 mutations in urinary bladder cancerP Berggren, G Steineck, J Adolfsson, et al.
BJU International|June 20, 2001
The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reactionT Wada, J Louhelainen, K Hemminki, et al.
British Journal of Cancer|February 13, 2001
Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinomaM Seddighzadeh, G Steineck, O Jansson, et al.
BJU International|November 18, 2003
The clinical implications of the prostate cancer prevention trialM Marberger, J Adolfsson, A Borkowski, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Age and Ageing|July 1, 1996
Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based studyA R Helgason, J Adolfsson, P Dickman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
Incidence and survival of rare urogenital cancers in EuropeO Visser, J Adolfsson, S Rossi, et al.
Urology|May 1, 1999
Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mLM Törnblom, U Norming, J Adolfsson, et al.
European Urology|September 23, 1998
Sexual dysfunction associated with the management of prostate cancerJ M Fitzpatrick, R S Kirby, R J Krane, et al.
BJU International|February 27, 2004
Monitoring the ERSPC trialH J De Koning, T Hakulinen, S M Moss, et al.
British Journal of Cancer|September 23, 1998
The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancerO T Jansson, E Morcos, L Brundin, et al.
British Journal of Cancer|June 1, 2001
p53 mutations in urinary bladder cancerP Berggren, G Steineck, J Adolfsson, et al.
BJU International|June 20, 2001
The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reactionT Wada, J Louhelainen, K Hemminki, et al.
British Journal of Cancer|February 13, 2001
Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinomaM Seddighzadeh, G Steineck, O Jansson, et al.
BJU International|November 18, 2003
The clinical implications of the prostate cancer prevention trialM Marberger, J Adolfsson, A Borkowski, et al.
Pageof 12